The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The company operates a chain of mid-sized multi-speciality hospitals
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
This launch is part of the company's strategy to expand its nutraceutical portfolio
Subscribe To Our Newsletter & Stay Updated
